Interestingly, higher expression of PALB2 was significantly associated with poorer overall survival (P < 0.01) in patients with stage III or nearby lymph node metastasis (N1, N2 or N3). Here, PALB2 is linked to metastatic malignant neoplasm in the lymph nodes.